# Radionuclide Production and Radiochemistry Core Description Core

> **NIH NIH P01** · UNIVERSITY OF WISCONSIN-MADISON · 2024 · $268,128

## Abstract

PROJECT SUMMARY – RADIONUCLIDE PRODUCTION AND RADIOCHEMISTRY CORE 1
The Department of Medical Physics controls three different particle accelerator laboratories equipped with a
variety of irradiation, radiochemistry, and radioanalytical equipment that will be used to investigate the symbiotic
effects of targeted radiotherapy (TRT) and the immunological methodologies of Projects 1-4. The Cyclotron
Laboratories’ principle site in the Wisconsin Institutes of Medical Research (WIMR) hosts a General Electric
PETtrace 16-MeV proton / 8-MeV deuteron cyclotron surrounded by 4000 square feet of laboratory space used
for radiochemical and accelerator research, as well as the routine production and international distribution of
numerous radionuclides to a global customer base. The cyclotron laboratory infrastructure accommodates tens
of Ci-quantities of radioactivity in automated processes using homemade and commercial equipment and is
internationally established as a leader in solid, liquid, and gas phase accelerator targetry, primarily for positron-
emission tomography (PET) radionuclide production. Spectroscopic/spectrometric analysis is accomplished with
multiple high purity germanium detectors and a variety of configurable electronic equipment. Most recently, our
research into alloy targetry for small, medical accelerators has enabled us to increase production of several
radionuclides of interest to previously unprecedented levels. This laboratory currently produces 89Zr, 76/77Br, 86Y,
52gMn and more than two dozen other radionuclides on a weekly basis for local use and shipment to over 60
collaborators, colleagues, pharmaceutical companies, and globally premier research institutions in the US and
abroad. The laboratory also hosts biosafety cabinets inside radiation areas for in vitro study of the unique
radionuclides we produce, adjacent to the laboratory space of the Small Animal Imaging Core. Finally, the
Department of Radiology recently finished construction of a GMP Radiopharmacy lab. The Radiopharmaceutical
Production Facility (RPF) is situated within the WIMR complex across the hall from the cyclotron facility. It houses
a new manufacturing area designed for the production of cGMP radiopharmaceuticals. This area is equipped
with multiple hot cells and synthesis modules and includes multiple quality control instruments to accommodate
segregation of clinical and preclinical production activities. A dispensing area designed in compliance with USP
<797> has the capability to compound and distribute radiopharmaceuticals. Although clinical trials are not the
aim of the PO1, we have the ability to rapidly translate the treatment paradigms discovered and developed within
the PO1 to the clinical trial stage. The specific aim of the Radionuclide Production and Radiochemistry Core
(RPRC) is to directly produce and supply pure imaging and therapy radionuclides and radiochemically synthesize
all imaging/therapy/immunomodulatory doses of radiopharmaceuticals ...

## Key facts

- **NIH application ID:** 10873224
- **Project number:** 5P01CA250972-05
- **Recipient organization:** UNIVERSITY OF WISCONSIN-MADISON
- **Principal Investigator:** Jonathan W Engle
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $268,128
- **Award type:** 5
- **Project period:** 2020-09-14 → 2026-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10873224

## Citation

> US National Institutes of Health, RePORTER application 10873224, Radionuclide Production and Radiochemistry Core Description Core (5P01CA250972-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10873224. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*